Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis
NCT06339008Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of lebrikizumab in perennial allergic rhinitis (PAR), sponsored by Eli Lilly and Company. Started Apr 2024; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT06339008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339008.